ClinicalTrials.gg
RecruitingNCT05665608PROFID EHRAUpdated Apr 1, 2026

Prevention Of Sudden Cardiac Death After Myocardial Infarction by Defibrillator Implantation

An interventional study of Implantable cardioverter-defibrillator (ICD) and Optimal Medical Therapy (OMT) in Sudden Cardiac Death and Myocardial Infarction, sponsored by Charite University, Berlin, Germany. Recruiting at 86 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-01.

Sponsored by Charite University, Berlin, Germany · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Nov 2023; still recruiting 3 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
3,595
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 43 studies in Death, Sudden, Cardiac with a site in Germany — 6 open to participants now, 7 under way, none of them phase 3. Death, Sudden, Cardiac · Germany.

Planned enrollment
Largest of 18
3,595 · median 180
Started
2023
with 1 other
No phase
13 of 43
3 open now
Registered
40th of 43
by date
Lead sponsor
3 of 43
Charite University, Berlin, Germany

Among the 43 studies in Death, Sudden, Cardiac with a site in Germany, this one has the largest planned enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2023, is one of 13 with no phase, and was the 40th registered.

Death, Sudden, Cardiac

364 studies on the registry are indexed under Death, Sudden, Cardiac; 84 are open to participants now.

Browse Death, Sudden, Cardiac studies →

Open to participants now

6 of the 43 studies in Death, Sudden, Cardiac with a site in Germany are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 63 Death, Sudden, Cardiac studies recruiting now, 42 (67%) set no upper age limit and 11 (17%) stop at 75 or younger; 22 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Death, Sudden, Cardiac with a site in Germany, or all of them as a file.
02

Study summary

Patients who have survived a myocardial infarction (MI) are at increased risk for sudden cardiac death (SCD) caused by ventricular tachycardia and ventricular fibrillation. A severely reduced left ventricular ejection fraction (LVEF) as a rough overall measure of impaired heart function after MI was shown to indicate a higher risk for SCD. Based on this observation, two landmark randomised trials, MADIT II and SCD-HeFT, were conducted between end of the 1990s and early 2000s. These trials compared the survival of patients with severely reduced LVEF who received an implantable cardioverter-defibrillator with the survival of patients being on medical therapy alone. They reported a significantly better survival of patients in the defibrillator arm and led to international guideline recommendations for routine implantation of defibrillators in survivors of MI with severely impaired LVEF as a means for primary prevention of SCD. Since then, the management of these patients has changed dramatically with the advent of a series of novel drug classes that reduce not only mortality but specifically SCD leading to a substantial decrease of the sudden death rates as well as of the rates of appropriate defibrillator therapies implanted for primary prevention of SCD. At the same time, the complication rates associated with the defibrilllator therapy remain significant without obvious decrease. Thus, the risk-benefit of routine defibrillator implantation for primary prevention of SCD in patients with severely reduced LVEF has substantially changed since the conduction of the landmark trials that established this therapy. Due to the inherent risks and considerable costs of the defibrillator, a novel randomised adequately powered assessment of the potential benefit or harm of the defibrillator in survivors of MI with reduced LVEF under contemporary optimal medical treatment (OMT) appears imperative.

OBJECTIVE:

To demonstrate that in post-MI patients with symptomatic heart failure who receive OMT for this condition, and with reduced LVEF ≤ 35%, OMT without ICD implantation (index group) is not inferior to OMT with ICD implantation (control group) with respect to all-cause mortality.

03

Conditions studied

  • Sudden Cardiac Death
  • Myocardial Infarction

Keywords

  • Implantable Cardioverter Defibrillator
  • Sudden Cardiac Death
  • Myocardial Infarction
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years.
  2. Naïve to implantation of any pacemaker or defibrillator
  3. Documented history of MI either as ST segment elevation myocardial infarction (STEMI) or as non-ST segment elevation myocardial infarction (NSTEMI) at least 3 months prior to enrolment.
  4. Symptomatic heart failure with (NYHA) class II or III.
  5. On OMT for at least 3 months prior to enrolment.
  6. ≤ 35% (at transthoracic echocardiography or cardiac magnetic resonance imaging [MRI] at least 3 months after MI).
  7. Signed .

Inclusion criterion I3 defines myocardial infarction according to the 2018 ESC/ACC/AHA/WHF Fourth Universal Definition of myocardial infarction

Exclusion criteria

Exclusion Criteria:

  1. Class I or IIa indication for implantation of an ICD for secondary prevention of SCD and ventricular tachycardia.
  2. Ventricular tachycardia induced in an electrophysiologic study.
  3. Unexplained syncope when ventricular arrhythmia is suspected as the cause of syncope.
  4. Class I or IIa indication for Cardiac Resynchronization Therapy (CRT)
  5. Foreseable violation of instruction for use (IFU) of the ICD device selected for implantation (valid for control group patients, only).
  6. Acute coronary syndrome or coronary angioplasty or coronary artery bypass grafting performed within 6 weeks prior to enrolment.
  7. Cardiac valve surgery or percutaneous cardiac valvular intervention performed within 6 weeks prior to enrolment.
  8. On the waiting list for heart transplantation.

    Class I or IIa indication for implantation of an ICD for secondary prevention of SCD and ventricular tachy-cardia has to be assessed according to the 2022 ESC Guidelines for the management of patients with ven-tricular arrhythmias and the prevention of SCD.

  9. Any known disease that limits to less than 1 year.
  10. Participation in another randomised clinical trial if study-specific treatment is still active at enrolment into PROFID EHRA.
  11. Previous participation in PROFID EHRA.

Parallel participation in sub-studies connected to this trial is permitted as well as in purely observational studies without any pre-defined intervention.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
3,595 participants (estimated)

Study arms

  • Active comparator
    Optimal Medical Therapy with ICD device therapy

    Patients will be treated according to Optimal Medical Therapy defined by ESC Guidelines for treatment of patients with heart failure / chronic coronary syndromes and will receive an ICD device

    Device: Implantable cardioverter-defibrillator (ICD) · Drug: Optimal Medical Therapy (OMT)

  • Experimental
    Optimal Medical Therapy without ICD device therapy

    Patients will be treated according to Optimal Medical Therapy defined by ESC Guidelines for treatment of patients with heart failure / chronic coronary syndromes and will not receive an ICD device

    Drug: Optimal Medical Therapy (OMT)

Interventions

  • DeviceImplantable cardioverter-defibrillator (ICD)

    A transvenous ICD consists of an electronic medical device and electrode leads. Besides the possibility to shock during arrhythmias the ICD can potentially terminate ventricular tachycardias by rapid pacing for short periods (small bursts of pacing). The subcutaneous defibrillator is an established and valid alternative to the transvenous ICD for the prevention of SCD, but in patients without an indication for bradycardia support, cardiac resynchronisation or antitachycardia pacing. The extravascular implantable cardioverter-defibrillator (EV ICD) system with substernal lead placement is a novel nontransvenous alternative to current available transvenous and subcutaneous ICDs.

  • DrugOptimal Medical Therapy (OMT)

    Patients will be treated according to Optimal Medical Therapy defined by the following guidelines: 1. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes 2. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure

06

What researchers measure

Primary outcomes

  1. Time from randomisation to the occurrence of all-cause death.

    Randomization to end of study

    Time frame: event-driven, expected about 15 months after last patient in

Secondary outcomes

  1. Time from randomisation to death from cardiovascular causes

    Time from randomisation to death from cardiovascular causes

    Time frame: Randomization to end of study (event-driven, expected about 15 months after last patient in

  2. Time from randomisation to sudden cardiac death

    Time from randomisation to sudden cardiac death

    Time frame: Randomization to end of study (event-driven, expected about 15 months after last patient in

  3. Time from randomisation to first hospital readmissions for cardiovascular causes after date of randomisation

    Time from randomisation to first hospital readmissions for cardiovascular causes after date of randomisation

    Time frame: Randomization to end of study (event-driven, expected about 15 months after last patient in

  4. Average length of stay in hospital during the study period

    Average length of stay in hospital during the study period

    Time frame: Randomization to end of study (event-driven, expected about 15 months after last patient in

  5. Quality of life (EQ-5D-5L) trajectories over time

    Quality of life (EQ-5D-5L) trajectories over time

    Time frame: At baseline and 12-month intervals thereafter

07

Study locations

83 of 86 sites recruiting
08

References and documents

Publications

  • Qian Y, Roque CR, Woods B, Iglesias Urrutia CP, Gc VS, Gur Arie M, Fischer D, Dagres N, Hindricks G, Manca A. Economic evaluation protocol for the PRevention Of sudden cardiac death aFter myocardial Infarction by Defibrillator implantation: the PROFID EHRA trial. BMJ Open. 2026 Jan 8;16(1):e097495. doi: 10.1136/bmjopen-2024-097495. PubMed 41506764 ↗
  • Dagres N, Gale CP, Nadarajah R, Boveda S, Merino JL, Nielsen JC, Kirchhof P, Kutyifa V, Taborsky M, Thiele H, Tijssen JGP, Verma A, De Potter T, Braunschweig F, Merkely B, Sommer P, Vernooy K, Suleiman M, Purerfellner H, Hindricks G; PROFID EHRA trial investigators. PRevention of sudden cardiac death aFter myocardial infarction by defibrillator implantation: Design and rationale of the PROFID EHRA randomized clinical trial. Am Heart J. 2026 Jan;291:37-43. doi: 10.1016/j.ahj.2025.07.071. Epub 2025 Aug 6. PubMed 40774643 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2023 (actual). Primary completion is estimated for Nov 2027, 48 months after the start.

Of 47 non-industry interventional studies with no phase under Death, Sudden, Cardiac, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 86. This study's planned 48 months is above that.

Counting every sponsor, half of 56 studies reached it within 42 months; a quarter within 17 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2022
First posted
Dec 27, 2022
StartActual
Nov 16, 2023
Primary completionEst.
Nov 30, 2027
CompletionEst.
Nov 30, 2027
Last update
Apr 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05665608
Responsible party
Daniela Fischer (Project Manager, Charite University, Berlin, Germany) — Principal investigator
First posted
Dec 27, 2022
Start date
Nov 16, 2023
Primary completion
Nov 30, 2027 (estimated)
Completion
Nov 30, 2027 (estimated)
Last update
Apr 1, 2026

Study contacts

Gerhard Hindricks, Prof
Contact
Gerhard.Hindricks@dhzc-charite.de
+49 30 450 513211
Nikolaos Dagres, MD
Contact
Nikolaos.Dagres@dhzc-charite.de
+49 30 450 665407
Gerhard Hindricks, Prof
principal investigator · Deutsches Herzzentrum der Charité, Department of Cardiology, Angiology and Intensive Care Medicine
Nikolaos Dagres, MD
principal investigator · Deutsches Herzzentrum der Charité, Department of Cardiology, Angiology and Intensive Care Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion